Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Akorn, Inc. (NASDAQ: AKRX) resulting from allegations that Akorn may have issued materially misleading business information to the investing public.

On January 9, 2019, Akorn disclosed that it had received a warning letter from the U.S. Food and Drug Administration following an inspection of Akorn’s Decatur, Illinois manufacturing facility. This inspection revealed that contrary to Akorn’s representations to shareholders, Akorn had failed to comply with multiple federal regulations pertaining to drug manufacturing. On this news, shares of Akorn fell $0.46 or over 11.6% to close at $3.48 on January 9, 2019.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Akorn investors. If you purchased shares of Akorn please visit the firm’s website at https://www.rosenlegal.com/cases-1497.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or zhalper@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.